Predicting invasive disease-free survival in ER-positive, HER2-negative early breast cancer using the PAM50 risk-of-recurrence score: a retrospective analysis using single-center long-term follow-up data of postmenopausal Japanese patients
Using long-term follow-up data, this study showed that the ROR score can predict the prognosis of ER-positive, HER2-negative early breast cancer in Japanese postmenopausal patients. Further investigations are required to confirm the prognostic value of the ROR score in Asian populations.
Authors
- Akane Higami (ORCID: https://orcid.org/0009-0006-4430-8666)
- Yosuke Yamada (ORCID: https://orcid.org/0000-0001-7952-2706)
- Masahiro Kawashima (ORCID: https://orcid.org/0000-0002-4738-8351)
- Masahiro Takada (ORCID: https://orcid.org/0000-0002-5954-1296)
- Nobuko Kawaguchi‐Sakita (ORCID: https://orcid.org/0000-0001-8667-1427)
- Yasuhide Takeuchi (ORCID: https://orcid.org/0000-0002-1262-2355)
- Kosuke Kawaguchi (ORCID: https://orcid.org/0000-0002-5115-7169)
- Ayane Yamaguchi (ORCID: https://orcid.org/0000-0002-8530-8383)
- Masakazu Toi (ORCID: https://orcid.org/0000-0003-1488-9958)
Institutions
- Kansai Medical University (JP)
- Kyoto University (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- Kyoto University Hospital (JP)
- Shiga Medical Center (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1007/s10147-024-02604-1
- Citations
- 2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Eli Lilly and Company
- Daiichi-Sankyo